Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.39 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987799 | 0.93 | TRPC3 (0.39) | TRPC3TRPC7ADORA3ADORA1ADORA2A | |
| SCHEMBL22988108 | 0.93 | TRPC3 (0.39) | TRPC3TRPC7ADORA3ADORA1ADORA2A | |
| SCHEMBL29646480 | 0.92 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AMAPT | |
| SCHEMBL22987600 | 0.92 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AMAPT | |
| SCHEMBL22987604 | 0.92 | FNTA (0.37) | ADORA3ADORA1USP30KCNK3KCNK9 | |
| SCHEMBL22988011 | 0.92 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AMAPT | |
| SCHEMBL22988202 | 0.91 | MMP1 (0.36) | TRPC3TRPC7ADORA3ADORA1USP30 | |
| SCHEMBL30393336 | 0.91 | TRPC3 (0.41) | TRPC3TRPC7ADORA3ADORA1ADORA2A | |
| SCHEMBL22987992 | 0.91 | TRPC3 (0.41) | TRPC3TRPC7ADORA3ADORA1ADORA2A | |
| SCHEMBL22988315 | 0.90 | ROCK2 (0.38) | USP30KCNK3KCNK9ENPP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | TRPC3 905/4885TRPC7 953/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.